The aim of this review is to report on the current status of prostate-specific membrane
antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of 68 Ga …

α-Emitting radionuclides have been approved for cancer treatment since 2013, with
increasing degrees of success. Despite this clinical utility, little is known regarding the …

Abstract Radium Ra-223 dichloride (radium-223, Xofigo®) is a targeted alpha therapy
approved for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic …

The theranostics concept using the same target for both imaging and therapy dates back to
the middle of the last century, when radioactive iodine was first used to treat thyroid …

Abstract Background The European directive on basic safety standards (Council directive
2013/59 Euratom) mandates dosimetry-based treatment planning for radiopharmaceutical …

Background Currently, the implementation of dosimetry in molecular radiotherapy (MRT) is
not well investigated, and in view of the Council Directive (2013/59/Euratom), there is a need …

Background The tumors of many patients with prostate cancer eventually become refractory
to androgen deprivation therapy with progression to metastatic castration-resistant disease …

OBJECTIVE. This article reviews recent developments in targeted radionuclide therapy
(TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine …

Abstract Background: Bone-metastatic, castration-resistant prostate cancer (bmCRPC)
represents a lethal stage of the most common noncutaneous cancer in men. The recent …

Targeted radiation therapy (TRT) is a strategy increasingly adopted for the treatment of
different types of cancer. The urge for optimization, as stated by the European Council …